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Proper podocyte function within the glomerulus demands a high and continuous energy
supply that is mainly derived from the respiratory chain of the inner mitochondrial mem-
brane. Dysregulations in the metabolic homeostasis of podocytes may result in podocyte
damage and glomerular disease. This article highlights the current knowledge about
podocyte energy supply by the respiratory chain.We review the regulation of mitochondrial
oxidative metabolism with regard to podocytopathy and discuss the latest understanding
of different mitochondrial dysfunctions of the podocyte in diabetic nephropathy and focal
segmental glomerulosclerosis (FSGS). We discuss genetic forms of mitochondriopathy of
the podocyte and end with recent knowledge about crosstalk between NADH and NADPH
and potential therapeutic options for podocyte mitochondriopathy. We aim to raise aware-
ness for the complex and interesting mechanisms of podocyte damage by impaired energy
supply that, despite of novel findings in recent years, is poorly understood so far.
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INTRODUCTION
Mitochondria are essential intracellular organelles that play a
major role in maintaining the energy homeostasis of cells by syn-
thesis of adenosine triphosphate (ATP) through oxidative phos-
phorylation. Mitochondria are also involved in cell signaling,
cellular differentiation, and control of cell cycle and growth (1).
The mitochondrial respiratory chain is composed of four pro-
tein complexes. NADH dehydrogenase (complex I), cytochrome c
reductase (complex II), cytochrome c oxidase (complex III), and
cytochrome c (complex IV) transfer electrons and protons across
the inner mitochondrial membrane generating the electrochemi-
cal gradient for ATP synthesis in complex V (Figure 1). Coenzyme
Q10 is important for shuttling electrons in the respiratory chain
(2–4). Some oxygen molecules are not reduced into water during
oxidative phosphorylation but form reactive oxygen species (ROS)
that can be converted into highly reactive radicals. These radicals
can lead to oxidative damage of mitochondrial DNA, peroxida-
tion of lipids and proteins, and activation of the mitochondrial
permeability transition pores (4).
The proper function of mitochondria depends on the nuclear as
well as the mitochondrial genes and the maintenance of oxidation–
antioxidation balance is required for an intact intracellular
signaling (5, 6).
Renal impairment in mitochondrial cytopathies most fre-
quently involve the tubular system with De Toni-Debré–Fanconi
syndrome being the most prominent example (7). However, an
increase in the production of ROS has been demonstrated in
experimental models of glomerular diseases too (8).
One cell type of special importance for the integrity of glomeru-
lar function is the podocyte. Podocytes are highly differentiated
glomerular epithelial cells with high energetic demands. Podocyte
injury results in malfunction of the glomerular filtration barrier
and is a crucial step in the development of many glomerular
diseases. Thus, a better understanding of the energy supply and
metabolic homeostasis of podocytes seems to be crucial. This arti-
cle highlights the current knowledge of podocyte energy supply
by the respiratory chain and the importance of mitochondria for
proper podocyte function.
ENERGY SUPPLY IN PODOCYTES
Podocytes demand a high energy supply to maintain various cel-
lular functions, including the organization of cytoskeletal and
extracellular matrix proteins (9).
In most studies mitochondrial function was characterized using
Seahorse Bioscience XF24 Extracellular Flux Analyzer to monitor
cell respiration (10–12). With this technique, different metabolic
states of cells can be measured in culture and blockers of different
complexes of the respiratory chain can be used. Basal oxygen con-
sumption rate of podocytes was about 55 pmol/min and the basal
rate of extracellular acidification was about 3 milli-pH units/min.
The complexV inhibitor oligomycin reduced oxygen consumption
rate to 45% of baseline and suggested that about 55% of cellular
oxygen consumption was coupled to ATP synthesis. As a complex I
inhibitor reduced oxygen consumption rate to 25% of the baseline
rates, mitochondrial respiration seems to be accounted for 75% of
the total cellular respiration in podocytes. The rest is accounted for
by proton leak (13). Proposed functions of proton leak include heat
production and prevention of oxidative stress caused by ROS (14).
Similar to the aforementioned studies, we recently mea-
sured podocyte metabolic profiles under diabetic conditions in
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FIGURE 1 | Described pathways affecting energy metabolism and ROS production in podocytes.
cell culture. Podocytes showed a significant increase in oxy-
gen consumption rate after prolonged exposure to high glu-
cose at baseline and also after treatment with the ATP synthase
inhibitor oligomycin. In contrary, mitochondrial respiration was
not changed in high-glucose condition in podocytes after the
inhibition of respiration by rotenone (12). Measured by NADH
turn over, metabolic activity of podocytes increased under TGF-β
and high glucose. The observed changes in mitochondrial func-
tion may lead to metabolic conditions that sensitize the podocyte
toward apoptosis. As both inhibition of glycolysis and of oxidative
phosphorylation reduced ATP levels in podocytes, it was con-
cluded that podocytes have limited ability to increase oxidative
phosphorylation or glycolysis, which makes them very susceptible
for dysfunctions in energy supply (12).
Furthermore, podocytes cannot increase glycolysis when mito-
chondrial function is blocked and thereby are not able to make
up the energy deficit (13). It has to be kept in mind that this data
comes from studies in isolated cultured podocytes. Conditions in
the kidney where podocytes are surrounded by other glomerular
cells might be different. Thus, the results from in vitro culture of
single cell types must be interpreted with caution.
The importance of mitochondrial function in the crosstalk
between different glomerular cells has been investigated by Daehn
et al. (15). Their studies suggested that segmental glomerulosclero-
sis develops due to podocyte endothelin-β1 that acts on glomeru-
lar endothelial mitochondria and caused oxidative damage (15).
Thus, the use of endothelin antagonists might be a therapeutic
opportunity to rescue this podocyte–endothelial crosstalk.
REGULATION OF MITOCHONDRIAL OXIDATIVE METABOLISM
IN PODOCYTES
Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) is a major regulator of mitochondrial oxidative
metabolism (16). Silent mating type information regulation 2
homolog 1 (SIRT1) regulates PGC-1α activity and energy metab-
olism. Overexpression of PGC-1α or peroxisome proliferator-
activated receptor-γ (PPARγ) itself protected podocyte against
damage by prevention of mitochondrial dysfunction (17).
Furthermore, the PGC-1α regulated mitochondrial function is
involved in doxorubicin induced podocyte injury. Doxorubicin
(trade name Adriamycin) is an anthracycline antibiotic used as a
drug in cancer. Its anticancer effects are believed to occur through
the inhibition of topoisomerase enzyme and subsequent blockage
of DNA resealing during cell replication (18). Moreover, doxoru-
bicin reduces the expression of PGC-1α and induces mitochondr-
ial dysfunction with increase in mitochondrial ROS production,
decrease in mitochondrial DNA copy number, and reduction of
ATP. On the other hand, PGC-1α overexpression was able to atten-
uate mitochondrial dysfunction and doxorubicin induced apop-
tosis of podocytes (19). The mitochondrial SIRT1–PGC-1α axis
also seems to play a role in aldosterone-induced podocyte dam-
age. Activation of this axis was able to ameliorate podocyte injury
due to aldosterone (16). These findings were confirmed by fur-
ther studies that showed an aldosterone dose-dependent increase
in the production of ROS and reduction in nephrin expression
(20). Thus, aldosterone-induced podocyte injury also seems to be
mediated by mitochondrial dysfunction.
Podocyte nephrin and podocin expression was also significantly
decreased in rats treated with advanced oxidation protein products
leading to proteinuria (21).
Similar results come from studies with immortalized mouse
podocytes where sustained application of NMDA triggered ROS
production that was also associated with reduced expression of
nephrin and podocin (22).
The inner mitochondrial membrane protein Mpv17 plays an
important role in peroxisomal metabolism of ROS (23). Mpv17
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knockout mice developed progressive glomerulosclerosis and pro-
teinuria and died from renal failure after 9–12 months. The
glomerular lesions in these mice were caused by excess of oxy-
gen radicals and accumulation of lipid peroxidation adducts in
the glomeruli (24).
In line with these findings, Mpv17 was shown to protect
podocytes against oxidative stress-induced injury (25). Thus,
Mpv17 seems to be important for mitochondrial homeostasis in
podocytes.
REGULATION OF PODOCYTE MITOCHONDRIA OXIDATIVE
STRESS IN DIFFERENT GLOMERULAR DISEASES
TGF-β is an unspecific model for cell stress. After stimulation
with TGF-β for 48 h, ROS levels increase by 32%. Furthermore,
TGF-β also activates the mammalian target of rapamycin (mTOR)
pathway and an mTOR inhibitor was able to ameliorate the TGF-
β stimulated increase in oxygen consumption rate, extracellular
acidification rate, and ATP (11). In our studies in cultured mouse
podocytes, we could find decreased activity of cytochrome c oxi-
dase (complex IV) and ATPase (complex V) of the respiratory
chain in podocytes after treatment with TGF-β. As for glucose, we
found increased NADH turnover as indicator for higher metabolic
activity in podocytes in the presence of TGF-β (12).
Podocyte-specific activation of TGF-β is among others associ-
ated with endothelin-1 release. This podocyte endothelin-1 medi-
ates mitochondrial oxidative stress and dysfunction in neighboring
endothelial cells via paracrine endothelin-1 receptor type A activa-
tion. In turn, endothelial dysfunction promotes podocyte apopto-
sis and podocyte loss leading to albuminuria, glomerulosclerosis,
and renal failure (15). Furthermore, exogenous TGF-β induces
podocyte apoptosis by caspase-3 activation and is associated with
upregulation of NADPH oxidase 4 (Nox 4) and increased ROS
levels in mice (26).
In podocytes, Nox4 is predominantly localized to mitochon-
dria and its upregulation markedly depolarizes the mitochondrial
membrane potential. Moreover, silencing of Smad3 and Nox4
prevented mitochondrial DNA reduction, restored mitochondrial
function, and decreased cellular apoptosis in puromycin aminonu-
cleoside (PAN) treated podocytes. Thus, the Smad3–Nox4 axis
might mediate mitochondrial dysfunction in podocyte damage
likely via ROS generation (27).
In the following section, we would like to give examples for
mitochondrial dysfunction in glomerular disease.
DIABETIC NEPHROPATHY
The most common cause for end-stage renal disease in developed
countries is diabetic nephropathy, and podocyte damage is an early
finding in the glomerular part of the disease. Several lines of evi-
dence suggest that mitochondrial dysfunction plays a critical role
in diabetic nephropathy.
We could show elevated activity of complex I and complex IV
of the respiratory chain as well as decreased activation of complex
V under acute high-glucose conditions in podocytes in previous
experiments. In contrast to that, podocyte activity of complex II
and III of the mitochondrial respiration chain was not affected by
high glucose (12).
Mitochondria are able to change their shape, number, and
intracellular distribution in response to different stimuli.
Mitochondria length and the degree to which they form closed
networks are determined by the balance between fission and fusion
rates of the mitochondria. Furthermore, fission and fusion are
important for growth and mitochondrial redistribution (28).
Dysregulations in mitochondrial dynamics can contribute to
mitochondrial dysfunction in diabetic conditions and mitochon-
drial fission was reported as a critical mediator of increased ROS
production in hyperglycemic conditions (17, 29).
The role of Rho-associated coiled coil-containing protein
kinase (ROCK) on mitochondrial dynamics was investigated by
Wang et al. (30). They found that ROCK mediates hyperglycemia-
induced mitochondrial fission by promoting dynamin-related
protein-1 recruitment to the mitochondria (30).
Rho-associated coiled coil-containing protein kinase has a
major role in mediating cytoskeleton rearrangements downstream
of Rho and is important for stress fiber formation, ROS produc-
tion, and cellular apoptosis (31–34). Inhibition of ROCK by fasudil
ameliorated albuminuria and progression of diabetic nephropathy
in a mouse model of diabetes (35).
Another example is that coagulation protease activated protein
C prevented as well as accumulation of oxidative stress markers
in the glomerulum as redox-regulating protein p66 in podocytes
in experimental diabetic nephropathy (36). These findings further
support the importance of podocyte mitochondrial homeostasis
for glomerular functions.
NEPHROTIC SYNDROME
Mitochondrial dysfunction and altered mitochondrial gene
expression have also been reported in patients with nephrotic
syndrome. Data supporting a critical role for mitochondria in
maintaining the glomerular permeability barrier also come from
studies in congenital nephrotic syndrome of the Finnish type. In
this podocyte disease, mitochondria-encoded respiratory-chain
components were downregulated whereas nuclear encoded sub-
units were unaffected. These results were interpreted as mitochon-
drial dysfunction with consequent abnormal production of ROS
(37). Changes in nephrin expression in congenital nephrotic syn-
drome of the Finnish type are believed to lead to defects in the
mitochondrial respiratory-chain functions resulting in excessive
ROS generation and accumulation of lipid peroxidation prod-
ucts with consequent dysfunction of the glomerular filtration
barrier (38).
Other mutations in mitochondrial respiratory-chain proteins
are those of aarF domain containing kinase (ADCK) (39). ADCK
have been shown to participate in coenzyme Q 10 biosynthesis.
Knockdown of ADCK4 in podocytes reduced their migration phe-
notype. The knockdown of ADCK4 recapitulated the nephrotic
phenotype in zebrafish. Moreover, a patient with steroid-resistant
nephritic syndrome with a homozygous ADCK4 mutation reached
partial remission under coenzyme Q10 treatment (40).
A role for podocyte mitochondrial injury in another glomeru-
lar disease was suggested by the finding that mutations in
enzymes related to coenzyme Q generation and in the mitochon-
drial tRNALeu(UUR) are associated with focal segmental glomeru-
losclerosis (FSGS) (41, 42). Different gene mutations have been
described to cause FSGS. Some of these mutations are related to
mitochondrial function. One example is mutations in Inverted
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formin 2 (INF2) that cause monogenetic familial FSGS (43, 44).
INF2 is localized in the endoplasmic reticulum and is required for
efficient mitochondrial fission in mammalian cells (45). Moreover,
INF2 is an actin-binding protein and is highly expressed in
the podocytes where it regulates polymerization and depolymer-
ization of the actin cytoskeleton (46). If this mitochondrial–
cytoskeletal interaction is also relevant in podocytes and causes
FSGS is unknown but from the discussion above it is highly
speculative.
Another mitochondrial gene that was described in FSGS is
prenyl diphosphate synthase subunit 2 (PDSS2). It is required for
synthesis coenzyme Q10 in humans and mutations in PDSS2 have
been associated with a significantly increased risk for FSGS and
collapsing glomerulopathy (47). Homozygous mice carrying kid-
ney disease mutations in the gene encoding PDSS2 (Pdss2kd/kd)
develop interstitial nephritis and die from end-stage renal disease.
In contrast, dietary supplementation with coenzyme Q10 rescued
proteinuria and interstitial nephritis in the Pdss2kd/kd mutant
mice (48).
Administration of PAN to rats produces severe proteinuria and
glomerular changes, mimicking minimal changes seen in humans.
Reduced mitochondrial DNA copy number led to lower levels
of respiratory-chain complex I in glomeruli in PAN model (49).
Furthermore, mice carrying mutant mitochondrial DNA devel-
oped FSGS and died within 6 months due to renal failure (50). In
patients, A-to-G transition at mitochondrial DNA position 3243
was associated with proteinuria and FSGS (51, 52). The FSGS phe-
notype as the renal manifestation of mitochondrial cytopathies
can even precede other manifestations of this genetic disease by
many years (53, 54).
Inherited coenzyme Q2 mutation is another category of mito-
chondrial cytopathies, characterized by proliferation of dysmor-
phic mitochondria, and primary glomerular damage. This mito-
chondriopathy was also referred to as coenzyme Q2 nephropathy
and electron microscopy showed dysmorphic mitochondria in the
cytoplasm of podocytes in this disease (55).
POTENTIAL THERAPEUTIC OPTIONS FOR PODOCYTE
MITOCHONDRIOPATHY
The relevance of mitochondria for proper podocyte function
makes it reasonable to look into therapeutic strategies targeting
mitochondrial metabolism.
However, coenzyme Q10 mitochondriopathy is currently the
only directly treatable mitochondrial defect (56). But recent find-
ings in interactions of podocytes metabolism give hope for further
substances to improve podocyte mitochondrial impairment.
First of all, we want to review the fundamental difference
between NADH and NADPH in biochemical reactions that should
not be mixed up. NADH is generated in a catabolic process from
glycolysis and citrate cycle whereas NADPH is a reducing agent and
donor for electrons and proteins. Mitochondria are able to gener-
ate NADPH by the transfer of reducing equivalents from NADH
to NADP+. NADPH can be used to reduce glutathione within the
mitochondrion and thereby controlling mitochondrial ROS (57).
Nox is prominently expressed in podocytes and is another
source of ROS production (58). An overproduction of ROS
was found in many podocyte injury models such as diabetic
nephropathy, membranous glomerular nephropathy, minimal
change disease, and FSGS (59).
Deficiencies of the vitamins B6, B9, and B12 can lead to
high homocysteine. Hyperhomocysteinemia-induced Nox activa-
tion was shown to be important for inflammatory mechanisms
through NOD-like receptor protein-dependent inflammasomes
(60). Moreover, Nox subunits aggregated and were activated
by lipid raft clustering and therefore were suggested to be a
leading mechanism in hyperhomocysteinemia-related oxidative
injury of podocytes. These injuries include reduced expression of
slit diaphragm molecules, cytoskeleton disarrangement, and cell
apoptosis (61, 62).
Mitochondria serve high levels of antioxidants and are able
to limit Nox activity. Mitochondria target ROS produced by Nox
but are also a significant source of ROS themselves. The cross
talk between mitochondria and Nox may represent a vicious cycle
of ROS production and it already has been tried to influence
this cross talk pharmacologically in mitochondrial dysfunctions
of podocytes.
Nox inhibition by diphenylene iodonium and apocynin could
attenuate podocyte injury (63). The mitochondrial DNA copy
number in podocytes is reduced in PAN model and consequently
leads to increase in oxidative stress and shortage of ATP synthesis.
Nox inhibition by apocynin decreased not only superoxide pro-
duction in podocytes but also inhibited endocytosis and urinary
albumin excretion in PAN rats (64). Nox is also the main source
of ROS in diabetic podocytes and contributes to the development
of diabetic nephropathy and metformin could decrease produc-
tion of ROS through reduction of NADPH oxidase activity (64).
Another example for enzymes that regulate mitochondria dysfunc-
tion and cause podocytopathy are glycogen synthase kinase (GSK)
3β. An inhibitor of GSK3β ameliorated proteinuria, attenuated
podocyte injuries, foot process effacement, and glomerulosclerosis
by alleviating mitochondria damages in podocytes (65). In stud-
ies, eplerenone treatment could prevent ROS overproduction in
aldosterone infused rats (66).
Furthermore, statins also seem to have beneficial effects on
mitochondrial function in podocytes. Rosuvastatin attenuated
angiotensin II-dependent increases in Nox activity and ROS
generation in cultured podocytes (67).
The Dahl salt sensitive rat is a rodent model of hypertension
that has many similarities with hypertension in human. The rats
develop salt sensitive hypertension, impaired renal function, and
proteinuria. In these rats, pre-treatment with pitavastatin was
podocyte protective by preventing NADPH subunits expression
(68). These findings are of special interest under the hypothesis
of an interaction of NADPH and mitochondrial energetic metab-
olisms. The PPAR-γ agonist rosiglitazone is an antidiabetic drug
that works as an insulin sensitizer. Rosiglitazone was also able to
protect podocytes against damage by prevention of mitochondrial
dysfunction (22).
CONCLUSION
In podocytes, proper mitochondrial function is indispensable
for maintenance and function of the glomerulus. Podocyte
mitochondriopathy is involved in many different acquired and
genetic glomerular diseases and influencing energy supply and
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antagonizing ROS production might be a potential therapeutic
strategy in the future.
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